Ichor Holdings, Ltd. (NASDAQ:ICHR) experienced a 16.0% decrease in short interest in March, totaling 1,783,716 shares. Despite recent insider selling, institutional ownership remains high at 94.81%, and analysts maintain a "Moderate Buy" rating with an average target price of $46.43. The company specializes in critical subsystems for semiconductor device fabrication and has seen its stock trade up recently.

InflaRx (NASDAQ:IFRX) shares rallied 32.5% during mid-day trading on Friday, reaching as high as $1.67 with significantly increased trading volume. Analyst sentiment is mixed but leans positive, with a "Moderate Buy" consensus and an average price target of $6.17. The clinical-stage biopharma company, focused on developing vilobelimab, currently has a market capitalization of $114.94 million and reported quarterly EPS of -$0.17.

Short interest in Intercorp Financial Services Inc. (NYSE:IFS) increased by 18.7% to 311,525 shares as of March 31st. The company recently increased its annual dividend to $1.80 per share, resulting in a 358.0% yield, and maintains a "Moderate Buy" analyst rating with an average target price of $48.00. Institutional investors have been adjusting their stakes in IFS, with some increasing their holdings.

Short interest in Ituran Location and Control Ltd. (NASDAQ:ITRN) significantly increased by 18.6% in March, reaching 144,480 shares, which represents about 0.7% of its shares. The company recently increased its quarterly dividend to $1.50 per share, resulting in a high annualized yield of 10.7%, though its payout ratio is a high 206.19%. Institutional investors have substantially boosted their holdings, and analysts generally rate the stock as a "Buy" with an average target price of $60.67.

Century Therapeutics (NASDAQ:IPSC) saw a significant increase in short interest in March, rising by 19.3% to over 10.2 million shares, representing 6.0% of its outstanding shares. This increase, coupled with a days-to-cover ratio of 5.6, suggests growing bearish sentiment and potential for a short squeeze. The company's stock traded at $2.60 midday, with a market capitalization of approximately $467.3 million, and despite beating quarterly EPS estimates, it remains unprofitable with analysts expecting a full-year EPS of -1.61.

Short interest in Information Services Group (NASDAQ:III) decreased by 15.8% in March to 582,091 shares, representing about 1.5% of the stock and a days-to-cover ratio of 2.3. Institutional investors hold 73.1% of ISG, with several firms recently increasing their positions. The company pays a quarterly dividend of $0.045, offering a 4.2% yield, and has a market cap of approximately $204 million.

HDFC Bank is set to announce its Q4 FY26 results on April 18, 2026, with profit after tax (PAT) projected to increase by 8.15% year-on-year to Rs 19,053 crore. The bank's Net Interest Income (NII) is expected to reach Rs 33,664 crore, a 4.9% YoY rise. Alongside the earnings, the Board of Directors will also consider a dividend recommendation for its shareholders.

InvenTrust Properties (NYSE:IVT) had its stock rating upgraded by Wall Street Zen from "sell" to "hold." Despite missing EPS estimates in its last quarterly earnings, the company delivered a slight revenue beat and issued strong FY2026 guidance above analyst expectations. The stock is trading near its 52-week high, with significant institutional ownership including an increased stake by Goldman Sachs.

Wall Street Zen upgraded Hubbell (NYSE:HUBB) from a "hold" to a "buy" rating, with a consensus "Moderate Buy" rating and a price target of $533.50 among analysts. The company reported strong quarterly earnings, beating expectations and raising its FY2026 EPS guidance. Despite recent insider share sales, institutional investors have increased their holdings, owning 88.16% of the company's stock.

Wall Street Zen has downgraded Jacobs Solutions (NYSE:J) from a "strong-buy" to a "buy" rating. Despite this, the stock holds a "Moderate Buy" average rating from analysts with an average price target of $154.60. The company reported Q1 EPS of $1.53, exceeding estimates, but missed revenue expectations and provided FY2026 EPS guidance.